QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

NCT07156682 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer
MSS/pMMR
QL1706

Interventions

DRUG: QL1706
DRUG: XELOX

Sponsor

Qilu Hospital of Shandong University